Marion McCourt compensation by year
REGENERON PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held| Component | FY2018 | FY2022 |
|---|---|---|
| Salary | $401,923 | $706,300 |
| Bonus | $0 | $0 |
| Stock awards | $4,671,325 | $2,159,974 |
| Option awards | $4,769,876 | $3,239,703 |
| Non-equity incentive | $372,281 | $780,462 |
| Pension and deferred compensation | $0 | $0 |
| All other | $9,250 | $13,500 |
| Total | $10,224,655 | $6,899,939 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REGENERON PHARMACEUTICALS, INC. DEF 14A filed April 21, 2023, accession 0001308179-23-000728, and prior-year filings. Open the filing on EDGAR.
How this page was built: the REGENERON PHARMACEUTICALS, INC. filed document, accession 0001308179-23-000728. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 10,000 | $7,214,900 | — |
| RSU | 3,338 | $2,408,334 | — |
| RSU | 2,973 | $2,144,990 | — |
| RSU | 2,500 | $1,803,725 | — |
| RSU | 2,000 | $1,442,980 | — |
| RSU | 731 | $527,409 | — |
| RSU | 537 | $387,440 | — |
| Option | 10,689 | — | $644.54 |
| Option | 10,971 | — | $726.53 |
| Option | 12,500 | — | $492.00 |
| Option | 3,412 | — | $372.46 |
Per the Outstanding Equity Awards at Fiscal Year-End table in REGENERON PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
20 Form 4 lines since the FY2022 proxy (filed April 21, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-16 | Sale | 10b5-1 | 49 | $960.31 | 10,557 |
| 2026-11-16 | Sale | 10b5-1 | 59 | $954.46 | 10,768 |
| 2026-11-16 | Sale | 10b5-1 | 63 | $965.62 | 10,331 |
| 2026-11-16 | Sale | 10b5-1 | 59 | $961.36 | 10,498 |
| 2026-11-16 | Sale | 10b5-1 | 42 | $963.70 | 10,415 |
| 2026-11-16 | Sale | 10b5-1 | 44 | $952.79 | 10,827 |
| 2026-11-16 | Sale | 10b5-1 | 41 | $962.44 | 10,457 |
| 2026-11-16 | Sale | 10b5-1 | 30 | $955.51 | 10,738 |
The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
REGENERON PHARMACEUTICALS’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Andrew Murphy | Executive Vice President, Research | $9,122,529 |
| Daniel Van Plew | Executive Vice President and General Manager, Industrial Operations and Product Supply | $8,853,537 |
| Robert Landry | Former Executive Vice President, Finance and Chief Financial Officer | $8,838,493 |
| Leonard Schleifer | President and Chief Executive Officer | $7,004,069 |
| Marion McCourt · this page | Executive Vice President, Commercial 10 | $6,899,939 |
| George Yancopoulos | President and Chief Scientific Officer | $6,593,696 |
The full REGENERON PHARMACEUTICALS compensation record
free company briefThis page is one person within REGENERON PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the REGENERON PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REGENERON PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.